Supply Agreement



  
 Exhibit 10.1

 SUPPLY AGREEMENT 
 THIS SUPPLY AGREEMENT (the “Agreement”) is as entered into as of this July 14, 2010 (“Effective Date”) between Questcor
Pharmaceuticals, Inc., a corporation organized under the laws of the State of California and having a place of business at 3260 Whipple Road, Union City, California 94587 U.S.A. (“Questcor”) and BioVectra Inc., a corporation organized
under the laws of Prince Edward Island and having a place of business at 11 Aviation Avenue, Charlottetown, Prince Edward Island, C1E 0A1 Canada (“BioVectra”) (each individually a “Party” and collectively the
“Parties”). 
 WITNESSETH: 
 WHEREAS, Questcor wishes to purchase from BioVectra and BioVectra desires to sell to Questcor the Product (as hereinafter defined); and 

WHEREAS, BioVectra represents that it has the technical and scientific experience and expertise necessary to perform manufacturing,
packaging, analytical testing and/or quality assurance services for the manufacturing and bulk packaging of such Product, and to handle materials associated with manufacture of such Product in a safe and environmentally sound manner; and 

WHEREAS, Questcor desires BioVectra to perform such services as set forth herein and manufacture such Product for Questcor, and BioVectra
desires to perform such services and manufacture such Product for supply to Questcor or its designee, all on the terms and conditions set forth in this Agreement; 
 NOW, THEREFORE, in consideration of the mutual covenants and promises set forth herein, the Parties agree as follows: 

 

	1.	DEFINITIONS  

 The following terms,
whether used in the singular or plural, shall have the meanings assigned to them below for purposes of this Agreement: 
  

	 	1.1	“Act” shall mean the United States Federal Food, Drug and Cosmetics Act, as amended, and the regulations promulgated under such Act. 


 

	 	1.2	“Affiliate” shall mean any corporation or non-corporate entity that controls, is controlled by, or is under common control with a Party. For purposes of this
Section 1.2, “control,” whether used as a noun or a verb, means the possession, directly or indirectly, of the power to affirmatively direct, or affirmatively cause the direction of, the management and policies of an entity, whether
through the ownership of voting securities, by contract, or otherwise. 

  

	 	1.3	“Agreement” shall mean this Supply Agreement and any Schedules appended hereto, as may be amended from time to time. 


 

	 	1.4	“API” shall mean Active Pharmaceutical Ingredient. 

  

	 	1.5	“Certificate of Compliance” shall mean a document indicating that each batch of Product was manufactured in compliance with cGMP, and that all Deviations were
evaluated for impact on Product. 


  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 









  

	 	1.6	“COA” shall mean Certificate of Analysis. 

  

	 	1.7	“Confidential Information” shall mean all proprietary information, data and know-how of each Party, whether disclosed orally or visually or in written,
graphic, electronic or other tangible form, which is disclosed by a Party or any of its Affiliates (the “Disclosing Party”) to the other Party or any of its Affiliates (the “Receiving Party”) or which the Receiving Party obtains
in the course of its performance pursuant to this Agreement, and which: (a) if in written, graphic, electronic or other tangible form, is labeled as confidential or proprietary; (b) if disclosed orally or visually, is identified as
confidential or proprietary at the time of disclosure and is confirmed to be confidential or proprietary by the Disclosing Party in writing to the Receiving Party within thirty (30) calendar days of such disclosure; or (c) should
reasonably be considered to be confidential or proprietary. With respect to Questcor, “Confidential Information” shall be deemed to also include (i) the Specifications; (ii) the Questcor Technology; and (iii) all business,
financial and technical data of Questcor including, but not limited to information regarding Questcor’s plans, plants, processes, products, costs, equipment, operations, marketing plans, forecasts, customers or suppliers. With respect to
BioVectra, “Confidential Information” shall be deemed to also include (i) its manufacturing processes and practices; (ii) the BioVectra technology; and (iii) all business, financial and technical data of BioVectra including,
but not limited to information regarding BioVectra’s plans, plants, processes, products, costs, equipment, operations, marketing plans, forecasts, customers or suppliers. 


 

	 	1.8	“Delivery Point” shall mean the Questcor ship-to location specified in the applicable Purchase Order for shipment of the ordered Product.


  

	 	1.9	“FDA” shall mean the United States Food and Drug Administration or any successor entity thereof having or performing substantially the same function.


  

	 	1.10	“Firm Order” shall mean a binding commitment in writing made by Questcor to purchase Product in accordance with Section 5. 


 

	 	1.11	“cGMP” shall mean all laws, guidelines and regulations applicable to the manufacture of Product including the current Good Manufacturing Practices as
specified in the United States Code of Federal Regulations, as the same may be amended or re-enacted from time to time, and international guidelines and regulations such as ICH Q7A. 


 

	 	1.12	“Non-Process Related Impurities” shall mean any substance that would not be present as a result of the process used to manufacture Product in compliance with
cGMP. 

  

	 	1.13	“Product” shall mean the chemical substances or the formulation(s) thereof listed in Schedule 1, attached hereto. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 2 of 42	 		 		 	









  

	 	1.14	“Product Recall” shall mean any recall, withdrawal, field correction or other action to recover possession of quantities of the Product shipped or sold to
Third Parties resulting in the event that (i) any government authority or other regulatory agency issues a request, directive or order that any Product or drug products derived from Product be recalled, (ii) a court of competent
jurisdiction orders such a recall, (iii) Questcor reasonably determines after consultation with BioVectra that any Products should be recalled because they do not conform to the Specifications or other requirements of this Agreement at the time
of shipment by BioVectra or (iv) Questcor reasonably determines that any Products should be recalled for any reason. 

  

	 	1.15	“Purchase Order” shall mean a written order for the purchase of Product duly executed by Questcor and transferred to BioVectra via mail, facsimile or
electronically, and setting forth the quantity of Product ordered, the required delivery date, the Delivery Point, the price for the Product, the Purchase Order number, the name of the requester, and any special terms and conditions relevant to the
particular Purchase Order (special terms and conditions are those that are not preprinted). 

  

	 	1.16	“Quality Assurance” shall mean the total organized arrangements made with the object of ensuring that Product is of the quality required for its intended use
and that quality systems are maintained so that all of the provisions set forth in Section 7.1.1 and in Section 9 of this Agreement are met. 

  

	 	1.17	“Quarter” shall mean the period of three consecutive calendar months ending 31 March, 30 June, 30 September and 31 December.


  

	 	1.18	“Change” or “Deviation” shall mean any planned or unplanned deviation, variance or change. 


 

	 	1.19	“Specifications” shall mean the specifications and quality assurance and other testing for the Product which will be attached hereto as Schedule 2, and made a
part hereof, as determined in accordance with the analytical methodology set forth therein, as such Specifications may be amended from time to time in writing by mutual agreement of the Parties. 


 

	 	1.20	“Third Party” shall mean any party other than Questcor, BioVectra and their respective Affiliates and agents. 


 

	 	1.21	“Section” shall mean a Section of this Agreement. 

  

	 	1.22	“NDA” means a New Drug Application as defined in and contemplated by the Act. 


 

	 	1.23	“DMF” means the Drug Master File pertaining to the manufacture of the Product. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 3 of 42	 		 		 	









  

	2.	SUPPLY OF PRODUCT 

  

	 	2.1	Supply and Purchase. BioVectra agrees to manufacture for and supply to Questcor or its designee on an exclusive basis such quantities of Product as Questcor may order
from BioVectra, and Questcor agrees to purchase such quantities of Product from BioVectra, in accordance with the terms and conditions of this Agreement. Questcor shall be obligated to purchase a minimum of [***] kilograms of Product under this
Agreement, however, Questcor shall not purchase in excess of [***] of Product in any given year. 

  

	 	2.2	Equipment. Questcor will provide to BioVectra at no cost to BioVectra the equipment required to manufacture Product in accordance with the manufacturing process
specified by Questcor, which equipment (and the location thereof) are listed on Schedule 5 attached hereto (the “Questcor Equipment”). BioVectra solely will be responsible for the costs of installation of the Questcor Equipment and
providing adequate facilities to house the Questcor Equipment. BioVectra will receive written authorization from Questcor prior to contracting to purchase additional equipment as may be required to produce Product for Questcor hereunder.


  

	 	2.3	Applicability and Hierarchy of Terms. The terms and conditions of this Agreement shall apply to any Purchase Order issued by Questcor to BioVectra during the term of
this Agreement for the Product that is the subject of this Agreement, whether or not this Agreement or its terms and conditions are expressly referenced in the Purchase Order. In the event of a conflict between the pre-printed terms provided in any
Purchase Order and the terms of this Agreement, the terms of this Agreement shall prevail. 

  

	 	2.4	Maintenance of Equipment. BioVectra shall be responsible for maintaining Questcor Equipment (and any other BioVectra equipment required to manufacture Product) in good
working order. Maintenance required of BioVectra includes, but is not limited to, preventative maintenance, calibration and repairs. 

  

	 	2.5	Use of Questcor Equipment. The Questcor Equipment is to be only used to manufacture the Product for Questcor hereunder. 


 

	3.	TERM AND TERMINATION 

  

	 	3.1	Term. This Agreement shall commence on the Effective Date and shall continue until written notice of no less than twelve (12) months is given by either Questcor or
BioVectra to the other (the “Term”). BioVectra will continue to provide manufacturing services and related testing, if notice of termination is given by Questcor or BioVectra, until Questcor transfers the manufacturing to an alternate site
and manufacturing at the alternate site is approved by the FDA or until four (4) years from the date of the notice of termination, whichever is shorter. 


  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 4 of 42	 		 		 	









  

	 	3.2	Termination for Cause. Without prejudice to any other available legal or equitable rights or remedies, the Parties may terminate this Agreement immediately upon written
notice to the other Party as follows: 

  

	 	3.2.1	Material Breach. Either Party may terminate this Agreement in the event of a material breach by the other Party of any material terms or conditions (including, but not
limited to, the non-Specification conformance of the Product) of the Agreement (“Default”), through no fault of the non-Defaulting Party, which remains uncured ninety (90) calendar days after the non-Defaulting Party provides written
notice of such Default to the Defaulting Party; provided however, that in the event that the Defaulting Party reasonably believes that the Default is incapable of being cured within such ninety (90) day period, then the Defaulting party shall
provide written notice to the non-Defaulting Party within seven (7) calendar days from the date of the notice of such Default, specifying that such Default is not capable of being cured within such period and the actions the Defaulting Party is
taking to diligently cure such Default, and the non-Defaulting Party may, in its sole discretion, agree in writing to extend the time period for curing such Default for up to an additional thirty (30) calendar days or such time as is reasonably
necessary to cure such Default. 

  

	 	3.2.2	Insolvency; Bankruptcy. Either Party may terminate immediately this Agreement in the event that the other Party (a) becomes insolvent; (b) makes an assignment
for the benefit of creditors; (c) files or has filed against it a petition in bankruptcy; (d) has a receiver appointed for its assets; or (e) is dissolved or liquidated. 


 

	 	3.2.3	Continued Manufacture. Termination under this Section 3.3 shall not cause Product to be unavailable to persons who are in need thereof. In the event this
Section 3.3 becomes applicable, the Parties agree to collaborate in good faith to develop a new source of manufacture thereof so as to keep Product available in the marketplace for the benefit of the users thereof. Questcor agrees to diligently
locate and qualify a new manufacturer of the Product and BioVectra agrees that it will not discontinue manufacture of the Product until such new manufacturer is qualified; provided, however, that if BioVectra’s inability to manufacture
Specification–conforming Product is the basis for termination under Section 3.3.1 above, then Questcor shall not obligate BioVectra to manufacture further non-conforming Product, but BioVectra agrees that it will, to the best of its
ability, correct any deficiencies at its own expense and manufacture Specification-conforming Product hereunder after any such notice of termination is received until such new manufacturer is qualified. 


 

	 	3.2.4	 Transfer of Materials and Equipment. If this Agreement is terminated under this Section 3.3, BioVectra shall promptly transfer to Questcor or
Questcor’s 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 5 of 42	 		 		 	










	 	 
designee, at Questcor’s written request and expense, all raw materials purchased by Questcor and supplied to BioVectra and all Questcor Equipment. 



 

	 	3.4	Return of Unused Maintenance Fees. Within Thirty (30) days of the effective date of any termination or expiration of the Agreement, Questcor will pay all amounts
owing to BioVectra for delivered Products in accordance with Section 4 of the Agreement or BioVectra will return Questcor any amount paid to BioVectra as a Minimum Annual Production Maintenance Fee that is not owed against such Products.


  

	4.	PRICE AND PAYMENT 

  

	 	4.1	Price of Product. The price for Product provided hereunder shall be as set forth in Schedule 3 to this Agreement. Such prices shall be firm through the entire Term and
through any subsequent contract extensions. 

  

	 	4.2	Price Adjustments. The price for Product may only be adjusted as provided in Schedule 3 hereto. 


 

	 	4.3	Billing and Payment. BioVectra will submit invoices to Questcor at the address designated in the applicable Purchase Order. Invoices shall include the following
information, where applicable: the description and quantity of Product delivered; the date of shipment of Product; the price for the Product; any applicable taxes, transportation charges or other charges provided for in the applicable Purchase
Order; and the applicable Purchase Order number. Questcor shall pay all invoices to BioVectra in U.S. dollars within thirty (30) days from when the Product is delivered to or on behalf of Questcor at the Delivery Point, provided that:
i) Questcor has received from BioVectra complete and accurate certificates of analysis and any other Process records required to be provided to Questcor pursuant to the provisions of Section 9 for such lot; ii) Questcor or its
designee has actually received the applicable lots of Product; and iii) the lot (or partial lot) is not rejected by Questcor or its designee. In the event that any shipment does not contain the entire invoiced quantity of Product, Questcor
shall only be obligated to pay for the quantity of Product actually received by or on behalf of Questcor. Full or partial payment by Questcor shall not result in a waiver of any of its rights under applicable law or this Agreement.


  

	 	4.4	Documentation Delays. For each day that such complete and accurate required documentation is delayed, the due and payable date of the related invoice will be delayed by
one (1) business day. Questcor will notify BioVectra if payment is to be delayed due to incomplete or inaccurate documentation stating in sufficient detail the reasons therefor. Questcor shall not be obligated to make payment for a lot of
Product if Product is rejected. If a lot of rejected Product is subsequently approved by Questcor, Questcor shall pay BioVectra for such lot within thirty (30) calendar days following such approval date. 


 

	 	4.5	 Disputed Amounts. If Questcor disputes in good faith all or any portion of any




  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 6 of 42	 		 		 	










	 	 
invoice submitted by BioVectra, Questcor shall be required to pay that portion of the invoiced amount that is not in dispute. In such event, Questcor shall notify BioVectra in writing of the
amount and nature of the dispute within thirty (30) calendar days after receipt of the applicable invoice, and the Parties shall promptly attempt in good faith to amicably resolve such dispute. Once the matter is resolved, Questcor shall
promptly pay any amount as may be due BioVectra. 


  

	 	4.6	Taxes. The Prices stated in this Agreement or a Purchase Order include all taxes except such sales and use taxes that BioVectra is required by law to collect
from Questcor. Such taxes, if any, will be separately stated in BioVectra’s invoice and will be paid by Questcor to BioVectra unless an exemption is available. BioVectra shall be responsible for the timely payment of all such taxes to the
applicable taxing authority, and BioVectra shall pay (without reimbursement by Questcor), and shall hold Questcor harmless against, any penalties, interest or additional taxes that may be levied or assessed as a result of the failure or delay of
BioVectra to pay any taxes. Questcor shall be responsible for any duties that result from BioVectra shipping Product to any Questcor designated Delivery Point. 


 

	5.	FORECASTS AND FIRM ORDERS 

  

	 	5.1	Forecasts. Questcor shall provide to BioVectra quarterly forecasts of its estimated requirements for Product (“Forecast”). Questcor shall provide such
Forecasts to BioVectra at least sixty (60) calendar days before the beginning of each calendar Quarter during the Term of this Agreement (beginning with the first Quarter in which Questcor intends to purchase Product hereunder), and such
Forecasts shall provide an estimate of Questcor’s requirements for Product for such Quarter and for the next succeeding three (3) Quarters. Such Forecasts shall be estimates for planning purposes only and shall not constitute commitments
by Questcor to purchase Product. Questcor shall only be obligated to purchase such quantities of Product as may be ordered by Questcor pursuant to a Purchase Order issued by Questcor to BioVectra, as provided in Section 5.2 below.


  

	 	5.2	Firm Orders. BioVectra will provide Product to Questcor pursuant to orders placed by Questcor in the form of individual Purchase Orders issued by Questcor to BioVectra.
At least forty-five (45) calendar days prior to the beginning of each Quarter during the Term of this Agreement, beginning with the first Quarter in which Questcor intends to purchase Product under this Agreement, Questcor shall issue a
Purchase Order for its requirements of Product for such Quarter. Questcor shall ensure that BioVectra has sufficient raw materials therefor in accordance with Section 9.2.1 below. 


 

	6.	DELIVERY; ACCEPTANCE; TITLE; RISK OF LOSS 

  

	 	6.1	 Delivery of Product. BioVectra will deliver Product to Questcor FOB, Charlottetown, per UCC § 2-319(1)(a), at the Delivery Point by the date(s)
specified in the applicable Purchase Order (the “Delivery Date”). BioVectra may not deliver 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 7 of 42	 		 		 	










	 	 
Product more than seven (7) calendar days prior to such Delivery Date without the prior written consent of Questcor. Questcor shall not be obligated to accept any untimely, incomplete
shipments less than sixty five percent (65%) of the Purchase Order amount or excessive shipments greater than one hundred thirty five percent (135%) of the Purchase Order amount, and such shipments, in whole or in part, may, at
Questcor’s option, be returned to BioVectra or held for disposition at BioVectra’s expense and risk. 


  

	 	6.2	Timely Delivery. In the event that BioVectra fails to deliver fully conforming Product by the Delivery Date, Questcor, at its option and in addition to any of its other
rights or remedies, may: (a) require BioVectra to expedite delivery of Product at BioVectra’s own expense; (b) extend the required Delivery Date; or (c) cancel the applicable Purchase Order. 


 

	 	6.3	Transportation. BioVectra will be responsible for routing of all freight, unless Questcor specifies otherwise in writing for a particular Purchase Order. Questcor shall
be responsible for all transportation charges on Product shipped from BioVectra to Questcor or its designee, subject to Section 6.2(a) above. BioVectra shall bear the cost of transportation for Product shipped to Questcor or its designee to
replace non-conforming or defective Product, and BioVectra shall bear the cost of transportation for Product returned to BioVectra by Questcor due to any defect or non-conformance, whether for the convenience of BioVectra or pursuant to a demand by
Questcor as provided herein. 

  

	 	6.4	Title and Risk of Loss. Title to and risk of loss of or damage to the Product sold hereunder shall pass to Questcor upon loading of the Product at BioVectra,
Charlottetown. Questcor shall assume the risk of loss of or damage to the Product after such loading of the Product at BioVectra, except to the extent that such loss or damage results from the negligence or willful misconduct of BioVectra or its
representatives, for which BioVectra shall retain the risk of loss of or damage to Product. 

  

	 	6.5	Acceptance; Rejection. All Product delivered by BioVectra to Questcor or its designee shall be subject to inspection by or on behalf of Questcor and Final Release (as
defined in Section 9 below) by Questcor’s Quality Assurance representative. Questcor may, on written notice to BioVectra within sixty (60) calendar days from receipt of delivery, reject any Product that does not fully conform to the
Specifications or requirements of this Agreement and the applicable Purchase Order, and Questcor may return any shipment or any portion of any shipment that does not fully conform. Payment for Product by Questcor shall not constitute acceptance
thereof. Questcor may revoke its acceptance of any Product in the event that any non-conformance of the Specifications is discovered after acceptance by Questcor. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 8 of 42	 		 		 	









  

	7.	REPRESENTATIONS AND WARRANTIES 

  

	 	7.1	Warranties by BioVectra. BioVectra represents and warrants to Questcor that: 


 

	 	7.1.1	Product. All Product provided to Questcor by BioVectra pursuant to this Agreement: 


 

	 	(a)	Will conform in all respects with the Specifications for such Product in effect at the time title to such Product passes from BioVectra to Questcor pursuant to this
Agreement; 

  

	 	(b)	Will not be adulterated or misbranded within the meaning of the Act or any similar law of any other jurisdiction; will be free from Non-Process Related Impurities; and
will be free of any defects; 

  

	 	(c)	Will not have been manufactured with Deviation(s) unless approved in writing by Questcor prior to release by BioVectra and subsequent delivery of the Product to
Questcor or its designee; 

  

	 	(d)	Will conform to and will be manufactured, packaged, labeled, stored and shipped in conformity with FDA regulations, cGMP requirements, the Specifications, the NDA
pertaining to the Product, and all applicable national, federal, state, provincial, and local laws, orders, rules and regulations, and 

  

	 	(e)	Will be manufactured, packaged and stored in facilities that are approved by the applicable regulatory authorities for the manufacture of Product at the time of such
manufacture, packaging and storage, to the extent such approval is required by law or regulation. 

  

	 	7.1.2	Title. BioVectra has good title to all Product provided to Questcor pursuant to this Agreement and passes such title to Questcor free and clear of any security
interests, liens, or other encumbrances. 

  

	 	7.1.3	Debarment. BioVectra represents and warrants that it is not debarred under subsections 306(a) or (b) of the Act and that it has not and will not use in any
capacity the services of any person or entity debarred under such law with respect to its performance of this Agreement. BioVectra will immediately notify Questcor in the event that it or any such person or entity is debarred during the term of this
Agreement. 

  

	 	7.1.4	No Conflict. The execution, delivery and performance of this Agreement by BioVectra does not conflict with any agreement, instrument or understanding, oral or written,
to which it is a party or by which it may be bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having authority over it; BioVectra is not currently a party to, and during the term of
this Agreement will not enter into, any agreements, oral or written, that are inconsistent with its obligations under this Agreement. 

  

	 	7.1.5	 Authority. BioVectra is validly existing and in good standing under the laws of the province of its incorporation and has the corporate power and
authority 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 9 of 42	 		 		 	










	 	 
to enter into this Agreement. This Agreement has been duly executed and delivered by BioVectra and constitutes the valid and binding obligation of BioVectra, enforceable against it in accordance
with its terms except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles. The
execution, delivery, and performance of this Agreement have been duly authorized by all necessary action on the part of BioVectra, its officers and directors. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 10 of 42	 		 		 	









  

	 	7.2	Breach of Warranty by BioVectra. In the event that any Product does not meet any of BioVectra’s warranties as provided in Section 7.1, in addition to any
other rights or remedies available to Questcor, BioVectra shall, at Questcor’s option, either use its best efforts to replace the non-conforming Product as soon as practicable or promptly refund the payments by Questcor for such non-conforming
Product. 

  

	 	7.3	Independent Laboratory Testing. If Questcor and BioVectra are unable to agree as to whether any Product conforms to the Specifications for such Product, the Parties
shall cooperate to have the Product in dispute analyzed by an independent testing laboratory of recognized repute selected by BioVectra and approved by Questcor, which approval shall not be unreasonably withheld, conditioned or delayed. The results
of such laboratory testing shall be final and binding on the Parties on the issue of conformance of the Product to the Specifications. If the Product is determined to so conform, then Questcor shall bear the cost of the independent laboratory
testing and pay for the Product in accordance with this Agreement. If the Product is determined not to conform, then BioVectra shall bear the cost of the independent laboratory testing, and BioVectra shall, at Questcor’s sole discretion, within
thirty (30) calendar days of the date of such determination, either replace the rejected Product at no cost to Questcor or promptly refund to Questcor the price paid for such Product. 


 

	 	7.4	Warranties by Questcor. Questcor represents and warrants to BioVectra that: 


 

	 	7.4.1	No Conflict. The execution, delivery and performance of this Agreement by Questcor does not conflict with any agreement, instrument or understanding, oral or written,
to which it is a party or by which it may be bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having authority over it; Questcor is not currently a party to, and during the term of
this Agreement will not enter into, any agreements, oral or written, that are inconsistent with its obligations under this Agreement. 

  

	 	7.4.2	Authority. Questcor is validly existing and in good standing under the laws of the state of its incorporation and has the corporate power and authority to enter into
this Agreement. This Agreement has been duly executed and delivered by Questcor and constitutes the valid and binding obligation of Questcor, enforceable against it in accordance with its terms except as enforceability may be limited by bankruptcy,
fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles. The execution, delivery and performance of this Agreement have been duly
authorized by all necessary action on the part of Questcor, its officers and directors. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 11 of 42	 		 		 	









  

	8.	PRODUCT RECALLS 

  

	 	8.1	Cooperation. In the event of any Product Recall, the Parties shall take all appropriate corrective actions and shall cooperate in the investigations and all necessary
activities surrounding the Product Recall. 

  

	 	8.2	Consultation. In the event that BioVectra or Questcor determines that Product should be recalled, the Parties shall consult with each other prior to taking any
corrective actions. Given that in the marketplace the Product is or will be associated with Questcor, in no event shall BioVectra institute a Product Recall without the prior written approval of an officer of Questcor. 


 

	 	8.3	Product Recall Caused by BioVectra. To the extent that any Product Recall results from any cause or event arising from the manufacturing, packaging, labeling, testing,
storage, or handling of the recalled Product by BioVectra, by any breach of BioVectra’s warranties, by any materials or facilities provided by BioVectra, or otherwise by the acts or omissions of BioVectra or its agents, BioVectra shall be
responsible for all expenses of such Product Recall. 

  

	 	8.4	Product Recall Caused by Questcor. To the extent that any Product Recall results from any cause or event arising from the Specifications, the raw materials supplied by
or on behalf of Questcor, marketing, distribution, shipment, handling (after title passes to Questcor) or sale of the recalled Product by Questcor or its Affiliates or designee at the Delivery Point, or the negligence of Questcor or its Affiliates
or designee at the Delivery Point, Questcor shall be responsible for all expenses of such Product Recall, including, without limitation, reasonable and necessary expenses incurred by BioVectra after written notification to Questcor and written
approval by Questcor therefor. 

  

	 	8.5	Expenses of Product Recall. In the event that a Product Recall is caused by BioVectra, BioVectra shall be liable to reimburse Questcor for all expenses of such Product
Recall, including, without limitation, the following: (i) all amounts paid by Questcor to BioVectra for the Product subject to the Product Recall, (ii) all reasonable costs and expenses incurred and not recovered by Questcor directly
resulting from such Product Recall (including, without limitation, shipping charges, hours spent coordinating the Product Recall, expenses of notification and destruction or return of the recalled Product, all costs associated with the distribution
of replacement Product, and all other costs incurred in connection with such Product Recall). The foregoing remedies shall be in addition to such other rights and remedies as Questcor may have under this Agreement and applicable law.


  

	 	8.6	 Disputes Regarding Cause of Product Recall. If the Parties are unable to agree as to which Party’s acts or omissions gave rise to a Product
Recall, such dispute shall be referred for decision to a mutually agreed upon independent expert of recognized repute (acting as an expert and not as an arbitrator, and who may be an attorney knowledgeable in FDA/pharmaceutical product recall law)
selected by Questcor and 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 12 of 42	 		 		 	










	 	 
approved by BioVectra, which approval shall not be unreasonably withheld, conditioned or delayed. The results of such independent expert shall be final and binding on the Parties on the issue of
which Party’s acts or omissions gave rise to the Product Recall. The costs of such independent expert shall be borne by the Party determined to be responsible for the Product Recall. 



 

	 	8.7	Notification Regarding Product Recall. Subject to Section 8.2 above, in the event that any Product Recall is required because Product violates applicable laws,
regulations, agreed upon Specifications, the NDA pertaining to the Product, or is deemed unacceptable for some other reason, whether or not such action is requested by any governmental agency, the initiating Party shall notify the Quality Assurance
Representative of the other Party as soon as possible, but not later than the end of the next business day following the decision to implement such action. 


 

	9.	QUALITY ASSURANCE 

  

	 	9.1	Change Control. BioVectra will utilize a documented system of procedures for the control of changes to raw materials, packaging materials, suppliers, equipment,
manufacturing methods, Product, intermediates and raw materials specifications, sampling, test methods, and release requirements, consistent with cGMPs, all applicable laws, rules and regulations, including the NDA pertaining to the Product, and
industry standards. BioVectra shall not implement any Change without the express prior written approval of Questcor. BioVectra will submit any proposed Change to Questcor in writing for its review, using the Deviation/Change Form attached hereto as
Schedule 4. The Parties will provide written responses to requests from the other pursuant to this Section 9.1 as soon as commercially possible but in no event more than twenty (20) business days from receipt of the request from the other
Party hereto. All updates to BioVectra’s DMF (and any other of BioVectra’s regulatory documents) related to the Product (or manufacture of the Product) are the responsibility of BioVectra. Updates to regulatory applications such as the NDA
pertaining to the Product are the responsibility of Questcor 

  

	 	9.2	Raw Materials. 

  

	 	9.2.1	Procurement of Raw Materials. BioVectra will utilize a documented system of procedures to evaluate, qualify and approve raw materials and suppliers.


 BioVectra is responsible for procuring suitable raw materials [***] from the approved and qualified sources.


  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 13 of 42	 		 		 	









  
 Questcor, at
Questcor’s expense, shall provide [***] to BioVectra in amounts required for BioVectra to fulfill its supply obligations to Questcor hereunder. In this regard, Questcor will provide sufficient quantity of appropriate quality [***] necessary to
fulfill Questcor’s obligation to purchase minimum quantities of Product as set forth in Section 2.1 above. 
  

	 	9.2.2	Inspection and Testing of Raw Materials. BioVectra must utilize documented material inspection plans and testing procedures. The results of this inspection and testing
must be in accordance with BioVectra established specifications and the NDA pertaining to the Product. 


BioVectra shall inspect all containers of raw materials [***] promptly upon receipt by BioVectra. BioVectra will inspect and/or test all
raw materials on a batch-by-batch basis. BioVectra may accept and release certain starting materials utilizing the COA with abbreviated or no additional testing. However, a minimum of an identification test is required unless the material is too
hazardous or reactive to sample. 
  

	 	9.2.3	Storage and Handling of Raw Materials. BioVectra agrees to store and handle the materials under appropriate conditions, consistent with cGMPs, all applicable laws,
rules and regulations, including the NDA pertaining to the Product, and industry standards. 

 BioVectra agrees to
store Product labeling materials under appropriate controlled and secured conditions, consistent with cGMPs, all applicable laws, rules and regulations, including the NDA pertaining to the Product, and industry standards. 

BioVectra shall have all necessary and appropriate controls in place to prevent cross-contamination of the raw materials and
intermediates used in the manufacture of Product from other chemicals stored, used, or manufactured by BioVectra, including but not limited to potent hormones, cytotoxic compounds, beta-lactams, highly potent drugs, biological preparations or
non-pharmaceutical chemicals. 
  

	 	9.2.4	 Transmissible Spongiform Encephalopathies (TSE) Compliance. Upon request by Questcor, BioVectra will promptly provide a written TSE declaration that
all materials [***] used by BioVectra to manufacture Product are free from animal derived material. BioVectra shall obtain such written 



  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 14 of 42	 		 		 	










	 	 
TSE declarations from each supplier of raw material used in the manufacturing of Product and shall maintain such TSE declarations for inspection by Questcor upon its request.



 If BioVectra is unable to provide the above mentioned declaration(s), BioVectra must comply with applicable
TSE laws and regulations and must supply all associated TSE documentation, as requested by Questcor, during the Term. Such documentation may include, but is not limited to, an application for a TSE Certificate of Suitability in accordance with
European Directive 75/318/EEC as amended by directive 1999/82/EEC, the note for guidance EMEA/410/01 rev1, as amended and AP-CSP (99)4, Appendix 2, as amended. 
  

	 	9.2.5	Certificate of Compliance for Animal Derived Components. BioVectra is to issue a Certificate of Compliance (signed by BioVectra’s Head of Quality Assurance) that
states that [***]. This Certificate of Compliance is to be included in each lot batch record. The format of a Certificate of Compliance approved by Questcor is attached hereto as Schedule 6. 


 

	 	9.3	Product Specifications. BioVectra will manufacture, package, label and handle all Product in conformance with, and in order for the Product to be in conformance with,
the Specifications and the NDA pertaining to the Product. 

  

	 	9.4	Manufacturing and Packaging of Product. BioVectra shall manufacture, package, and label all Product in accordance with specific procedures and instructions consistent
with cGMPs, all applicable laws, rules and regulations, and the NDA pertaining to the Product, and industry standards. 

 BioVectra will prepare all appropriate and required manufacturing and packaging batch documentation for each batch of Product manufactured pursuant to this Agreement. BioVectra shall retain such batch
documentation in accordance with any document retention schedules provided by Questcor and as required in order to comply with applicable regulatory requirements. BioVectra will make any such batch documentation available for review and inspection
by Questcor and/or any regulatory personnel, and BioVectra shall provide to Questcor all such batch documentation upon the expiration or termination of this Agreement or upon request by Questcor. 

BioVectra shall have all necessary and appropriate controls in place to prevent cross-contamination of Product and intermediates used in
the manufacture of Product from other chemicals stored, used, or manufactured by BioVectra, including but not limited to potent hormones, cytotoxic compounds, highly potent drugs, biological 

  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 15 of 42	 		 		 	









 
preparations or non-pharmaceutical chemicals. Beta-lactam and cephalosporin antibiotics must be handled in facilities separate from those in which Product is manufactured and packaged.

 BioVectra shall assure that materials in its possession containing any potentially hazardous component are sufficiently
isolated and segregated from the Product manufactured for Questcor. BioVectra shall make Questcor aware of the presence of any potentially hazardous products and will adhere to all reasonable requests of Questcor with respect to the storage of such
materials. BioVectra will adhere to any regulatory requirements or restrictions with respect to the storage of raw materials, intermediates, or Product. 
 BioVectra will destroy any waste material or labeling materials in a secure and legal manner, in order to prevent unauthorized use and/or environmental problems. 

 

	 	9.5	Inspection and Testing of Product. BioVectra will perform the inspection and testing of Product as provided in Schedule 2 to this Agreement. Questcor reserves the right
to inspect and/or test all batches of the Product delivered to Questcor or any Questcor designee. 

 BioVectra
will provide to Questcor a complete copy of the entire batch record that shall include but not be limited to (i) COA, (ii) executed batch record, (ii) all testing results conducted by BioVectra and/or independent testing labs
contracted by BioVectra, (iii) Certificate of Compliance concerning animal derived components (per Section 9.2.5 above), (iv) Deviation final reports that have been approved by Questcor, and (v) any other associated documentation
mutually agreed to by both Parties for each batch of Product delivered. BioVectra will deliver the complete batch record and associated documents with each batch no later than the time of delivery of the batch by BioVectra to Questcor or its
designee. 
  

	 	9.6	Notification and Approval of Deviations. BioVectra will have a documented system for handling Deviations, Deviation investigations, and corrective actions. All
Deviations will be investigated and fully documented by BioVectra. BioVectra is to notify Questcor within five (5) business days from the time that BioVectra discovers the Deviation. All Deviations (including the final report which outlines the
Deviation, investigation and corrective actions taken) must be reviewed and approved by Questcor. BioVectra will retain such documentation as part of the batch documentation for the batch affected. Shipment of a lot shall not occur until Questcor
has approved all Deviations. 

  

	 	9.7	Release and Shipment of Product. BioVectra has the responsibility to release the Product for shipment to Questcor or its designee, provided, however, that if Product
does not meet the Specifications in all respects, without any Deviations not approved by Questcor, the Product can be released only with the prior written consent of Questcor. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 16 of 42	 		 		 	









  
 BioVectra will not
ship any Product to any Delivery Point, as identified by Questcor, until the Product is released. 
  

	 	9.8	Retained Samples of Product. BioVectra shall retain samples of all Product batches in accordance with the retention schedule mutually agreed upon but for no less than
seven (7) years. The amount of such retained samples shall be of sufficient quantity to conduct at least full Specification analyses in duplicate. BioVectra shall store the retained samples under appropriate Product label storage conditions in
a secure area and in a suitable storage facility, consistent with cGMPs, all applicable laws, rules and regulations, and industry standards. All such samples shall be available for inspection by Questcor during any audit by Questcor of
BioVectra’s facilities or upon reasonable notice to BioVectra by Questcor. 

  

	 	9.9	Storage of Product. BioVectra agrees to store the Product under appropriate Product storage conditions and in a secure area, consistent with cGMPs, all applicable laws,
rules and regulations, and the NDA pertaining to the Product, and industry standards. 

  

	 	9.10	Annual Product Quality Review(s). BioVectra will prepare and provide to Questcor a Product Quality Review Report (“PQRR”) on an annual basis, consisting of a
systems review to confirm 1) processing, 2) that Product consistently meets the Specifications and limits, 3) identification of any significant trends (data or nonconformance) and 4) continued support for established retest dating. Such PQRR shall
be provided by BioVectra to Questcor within thirty (30) calendar days from each one-year anniversary of the Effective Date of this Agreement or such other times as may be mutually agreed upon by the Parties. 


 

	 	9.11	In addition, Questcor and BioVectra will meet as necessary to review quality issues related to the obligations and responsibilities as described in this Agreement.
During this review, quality issues related to the past production by BioVectra of Product will be reviewed. The information presented and discussed during this review meeting will be documented by BioVectra and submitted to Questcor for its review
and approval. 

  

	 	9.12	Complaints about the Product. BioVectra will have a documented system to receive, communicate with Questcor, investigate, and resolve all complaints related to Product.
BioVectra will investigate the complaints as requested by Questcor and provide a written report on the results of the investigation to Questcor within thirty (30) calendar days. If necessary, Questcor will communicate with the customers and/or
the regulatory authorities the results of the complaint investigation. 

  

	 	9.13	Returned Goods. BioVectra will have a documented system for handling returned goods, consistent with cGMPs, all applicable laws, rules and regulations, and industry
standards. 

  

	 	9.14	 Audits and Inspections of Facilities and Product. BioVectra will notify Questcor of any inspections of BioVectra’s facilities used in the
manufacture or storage of 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 17 of 42	 		 		 	










	 	 
Product, or other actions that could potentially impact Product, by any regulatory agencies or other enforcement entities. BioVectra will provide Questcor with a written summary describing all
results of inspections within thirty (30) days after the visit or inquiry. If any inspection is specifically related to the Product, BioVectra shall promptly inform Questcor and give Questcor representatives the opportunity to participate, at
Questcor’s expense, in the inspection. 


 Questcor reserves the right to audit BioVectra’s
facilities, systems, and documentation as they relate to the manufacture and control of Product, and to assure compliance with this Agreement, including but not limited to Product manufacturing, storage, quality control, environmental compliance and
health and safety compliance. These audits may be performed on a periodic basis at times mutually agreed upon by both Parties. The right to audit will also cover any subcontractors (e.g. a contract laboratory) if utilized by BioVectra. Questcor also
reserves the right to be present at BioVectra’s facility during the manufacture of Product. 
  

	10.	CONFIDENTIALITY 

  

	 	10.1	Restrictions. Except as otherwise provided in this Section 10, during the Term of this Agreement, including any renewals thereof, and for a period of ten
(10) years thereafter: (i) each Party will hold the Confidential Information of the other Party in strict confidence and will protect such Confidential Information with at least the same degree of care that it exercises with respect to its
own Confidential Information, which shall be no less than a reasonable degree of care; (ii) neither Party will disclose the Confidential Information of the other without in each instance obtaining the prior written consent of the Disclosing
Party; (iii) each Party will use the Confidential Information of the other only as is necessary to fulfill its obligations under this Agreement and for achieving the purposes of this Agreement and not for any other purpose; and (iv) each
Party will limit internal disclosure of the other Party’s Confidential Information to its and its Affiliates’ officers, employees or agents on a need-to-know basis for purposes of fulfilling its obligations under this Agreement and
achieving the purposes of this Agreement, provided, however, that each of these officers, employees and agents shall have been advised of the confidential nature of the Confidential Information, are bound by these restrictions, and have been
directed to treat such information confidentially and otherwise comply with this Agreement. In any event, the Receiving Party shall be responsible for any breach of the terms of this Agreement by any of its or its Affiliates’ officers,
employees or agents. 

  

	 	10.2	 Exceptions. Notwithstanding the provisions of Section 10.1 above, neither Party shall have any obligations with respect to information which the
Receiving Party can demonstrate: (i) is or becomes generally available to the public other than through the Receiving Party’s disclosure; (ii) was in the Receiving Party’s possession prior to it being furnished by or on behalf of
the Disclosing Party, provided that the Receiving Party’s source had the legal right to disclose such information; (iii) becomes available to the Receiving Party on a non-confidential basis from a source other than the




  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 18 of 42	 		 		 	










	 	 
Disclosing Party, provided that the Receiving Party’s source had the legal right to disclose such information; (iv) is or becomes independently developed by an employee of the Receiving
Party without access to the Confidential Information and without violating any of the Receiving Party’s obligations under this Agreement; (v) is required to be disclosed to any governmental agency for purposes of obtaining patents or
approvals to test or market the Product; or (vi) is required to be disclosed by order of any court of competent jurisdiction or other governmental authority, provided, however, that the Receiving Party shall provide to the Disclosing Party
prompt written notice (but in no event less than fourteen (14) calendar days) prior to such disclosure so that the Disclosing Party may attempt by appropriate legal means to limit such disclosure at its cost and expense, and the Receiving Party
shall endeavor in good faith to limit the disclosure and maintain the confidentiality of such Confidential Information to the maximum extent possible, provided, however, that nothing in this Agreement shall be deemed to require the Receiving Party
to violate and law or judicial order. 


  

	 	10.3	Return of Confidential Information. Each Party agrees to promptly return all Confidential Information and all copies thereof to the Disclosing Party, and to destroy all
information created by Receiving Party that contains Confidential Information furnished by Disclosing Party, at the expiration or termination of this Agreement, or at any time prior to the expiration or termination of this Agreement upon the
Disclosing Party’s written request (provided, however, that the Receiving Party shall not be required to return such Confidential Information to the Disclosing Party prior to the expiration or termination or this Agreement that the Receiving
Party reasonably requires in order to perform its obligations under this Agreement). Upon request of the Disclosing Party, the Receiving Party shall provide written certification of such return or destruction. Notwithstanding the foregoing, the
Receiving Party may retain one (1) copy of such Confidential Information in its legal archive files solely for purposes of identifying such Party’s obligations under this Agreement or complying with other legal requirements, including
under the Act. Notwithstanding the Receiving Party’s return and destruction of the Confidential Information, Receiving Party will continue to be bound by its obligation of confidentiality as otherwise provided herein. 


 

	11.	INDEMNIFICATION 

  

	 	11.1	 Indemnification by Questcor. Except as otherwise specifically provided in Section 11.2 below, Questcor shall indemnify, defend and hold harmless
BioVectra, its Affiliates, and its and their respective directors, officers, employees, agents, successors and assigns from and against any and all claims, demands, losses, damages, judgments, settlement amounts, suits, actions, liabilities, costs
and expenses (including, but not limited to, court costs and reasonable attorneys’ fees) arising out of or resulting from: (i) any negligence or willful misconduct of Questcor, its employees or agents in the use, handling (after title has
passed to Questcor), shipment, distribution, marketing or sale of any Product; (ii) any injury or death to persons or 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 19 of 42	 		 		 	










	 	 
theft of or damage to property resulting from the use, handling (after title has passed to Questcor), shipment, distribution, marketing or sale of any Product unless caused by defective or
non-conforming Product; (iii) the material default by Questcor in the performance of any obligation hereunder or Questcor’s breach of any of its warranties or representations hereunder; (iv) any labeling of any Product to the extent
that such labeling has been supplied by or at the direction of Questcor and applied in accordance with instructions from Questcor; and/or (v) any proceeding instituted by or on behalf of a Third Party based upon a claim that the manufacture,
use or sale of the Product infringes any intellectual property right, including any patent, trademark or trade secret of such Third Party. 


  

	 	11.2	Indemnification by BioVectra. Except as otherwise specifically provided in Section 11.1 above, BioVectra shall indemnify, defend and hold harmless Questcor, its
Affiliates, and its and their respective directors, officers, employees, agents, successors and assigns from and against any and all claims, demands, losses, damages, judgments, settlement amounts, suits, actions, liabilities, costs and expenses
(including, but not limited to, court costs and reasonable attorneys’ fees) arising out of or resulting from: (i) any injury or death to persons or theft of or damage to property caused directly or indirectly by defective or non-conforming
Product or by the negligence or willful misconduct of BioVectra, its employees or agents; (ii) the material default by BioVectra in the performance of any obligation hereunder or BioVectra’s breach of any of its warranties or
representations hereunder; (iii) BioVectra’s negligent acts or omissions or willful misconduct in the manufacture, labeling, packaging, storage, or handling of Product; and/or (iv) BioVectra’s failure to comply with the
provisions of any applicable law or regulation, including, but not limited to, the NDA pertaining to the Product, those of the Act and those relating to the environment and health and safety. 


 

	 	11.3	 A Party (the “Indemnitee”) which intends to claim indemnification under this Section 11 shall promptly notify the other Party (the
“Indemnitor”) in writing of any action, claim or other matter in respect of which the Indemnitee or any of its Affiliates, or any of their respective directors, officers, employees or agents, or any Third Party entitled to indemnification
under Sections 11.1 or 11.2 above, intend to claim such indemnification; provided, however, the failure to provide such notice within a reasonable period of time shall not relieve the Indemnitor of any of its obligations hereunder except to the
extent the Indemnitor is prejudiced by such failure. The Indemnitee shall permit, and shall cause its Affiliates, and their respective directors, officers, employees and agents to permit, the Indemnitor, at its discretion, to settle any such action,
claim or other matter and the Indemnitee agrees to the complete control of such defense or settlement by the Indemnitor; provided that such settlement does not adversely affect the Indemnitee’s rights hereunder or impose any obligations on the
Indemnitee in addition to those set forth herein in order for it to exercise such rights. No such action, claim or other matter shall be settled without the prior written consent of the Indemnitee, and the Indemnitee shall not be responsible for any
attorneys’ fees or other costs incurred other than as provided 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 20 of 42	 		 		 	










	 	 
herein. The Indemnitee, its Affiliates, and their respective directors, officers, employees and agents shall reasonably cooperate with the Indemnitor and its legal representatives in the
investigation and defense of any action, claim or other matter covered by this indemnification. The Indemnitee shall have the right, but not the obligation, to be represented by counsel of its own selection and at its own expense.



  

	 	11.4	The provisions of this Section 11 shall survive the expiration or termination of this Agreement. 


 

	12.	LIMITATIONS ON LIABILITY 

  

	 	12.1	In no event shall either Party be liable to the other Party for any indirect, incidental, special, consequential, punitive or exemplary damages (including, but not
limited to, damages based upon lost profits, business interruption, lost business, or lost savings) for any acts or failure to act under this Agreement, even if it has been advised of their possible existence. Notwithstanding the foregoing, there
shall be no limitation on a Party’s liability for claims: a) arising out of a breach of its confidentiality obligations under this Agreement; or b) arising out of its indemnification obligations under this Agreement. 


BioVectra shall reimburse Questcor for loss or damage to (i) raw materials purchased by Questcor, supplied to BioVectra and stored
at BioVectra and (ii) Questcor Equipment. Reimbursement of raw materials and equipment shall be at replacement value. 
  

	13.	INSURANCE 

 Each
Party shall obtain and maintain at its expense during the term of this Agreement and for a period of at least one (1) year after the expiration or termination of this Agreement, all insurance coverage required by law as well as appropriate
insurance coverage to protect against any and all claims or liabilities that may arise directly or indirectly as a result of its performance under this Agreement. In this regard, each Party shall maintain at least three million dollars ($3,000,000)
of product liability insurance for the duration of this Agreement and for five (5) years thereafter. 
  

	14.	MISCELLANEOUS 

  

	 	14.1	 Independent Contractors. The relationship between Questcor and BioVectra is that of independent contractors and nothing contained in this Agreement
shall be deemed to constitute or create any other relationship, including employment, partnership, agency or joint venture, between Questcor and BioVectra. Neither Party shall have any express or implied right or authority to employ any person as
agent or employee for or on behalf of the other, or to bind or attempt to bind the other Party to any obligation with any Third Party. BioVectra has and retains full control and supervision over the performance of its obligations hereunder and over
the 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 21 of 42	 		 		 	










	 	 
employment, direction, compensation and discharge of all employees, agents and subcontractors it utilizes in the performance of such obligations. BioVectra is responsible for its acts and
omissions and those of its employees, agents and subcontractors. 


  

	 	14.2	Assignment and Subcontracting. BioVectra shall not assign any of its rights nor delegate or subcontract any of its duties under this Agreement without the prior written
consent of Questcor. Any such attempted assignment of rights or delegation or subcontracting of duties without the prior written consent of Questcor shall be void and ineffective. Any such assignment, delegation or subcontracting consented to by
Questcor shall not relieve BioVectra of its responsibilities and liabilities hereunder, and BioVectra shall remain liable to Questcor for the conduct and performance of each permitted delegate and subcontractor hereunder. Questcor shall have the
right to assign this Agreement to any Third Party, provided, however, that such Third Party assumes in writing the rights, duties and obligations of Questcor as set forth in this Agreement and guarantees such in writing to BioVectra.


  

	 	14.3	Advertising and Publicity. BioVectra shall not use the name or any trademark, trade name, logo or symbol of Questcor or any Questcor Affiliates, or disclose any matters
relating to this Agreement, in any advertising, promotion, press/publicity release, written articles or other form of public written disclosure without the prior written consent of Questcor. Questcor shall not disclose and matters relating to this
Agreement nor issue any press/publicity release referring to BioVectra without the prior written permission of BioVectra, which shall not be unreasonably withheld, conditioned or delayed. It is understood by BioVectra that Questcor, as the holder of
the Product NDA, will have to make certain disclosures and regulatory filings indicating that BioVectra is manufacturing the Product for Questcor. 

  

	 	14.4	Force Majeure. Neither Party shall be liable for delays in performance or nonperformance in whole or in part due to any causes that are beyond its reasonable
control and not due to its acts or omissions, such as acts of God, fire, strikes, embargo, war, acts of terrorism, acts of the government, or any other similar causes, but not acts which could be anticipated, such as raw material
price increases, shortages of raw materials, or an increase in demand for Product. In such event, the Party delayed shall promptly give notice to the other Party, and shall endeavor in good faith to eliminate, cure or overcome any such causes and to
resume performance of its obligations as soon as possible. The Party affected by the other Party’s delay may elect to: (a) suspend performance and extend the time for performance for the duration of the event, or (b) cancel all or
part of any part of the unperformed part of this Agreement or any individual Purchase Order(s) hereunder. 


Questcor shall have the right, but not the obligation, to terminate this Agreement under this Section 14.4 upon not less than ninety
(90) days written notice to BioVectra if BioVectra cannot, or appears unable in Questcor’s good faith opinion, to supply Product hereunder to Questcor to meet Questcor’s needs therefor due to a condition of Force Majeure. 

  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 22 of 42	 		 		 	










	 	14.5	Notices. Any notice, communication, or statement required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been
sufficiently given when delivered to the person(s) listed below in any of the following manners: (i) in person; (ii) by registered or certified mail, postage pre-paid, return receipt requested; (iii) by a
nationally-recognized courier service guaranteeing next-day delivery, charges prepaid; or (iv) by facsimile with the original promptly sent by any of the foregoing manners. Notice or receipt of a particular communication shall be
considered given or received when actually received. Either Party may, by notice to the other, change the names and addresses given below for receipt of notices. 


 

	 	14.6	If to BioVectra: 


BioVectra Inc. 
 Attn: Chief Executive Officer 
 11 Aviation Avenue 

Charlottetown, Prince Edward Island 

C1E0A1 Canada 
 Facsimile No.: (902) 566-9116 
 With a copy to: 

BioVectra Inc. 
 Attn: Chief Operating Officer 
 11 Aviation Avenue 

Charlottetown, Prince Edward Island 

C1E0A1 Canada 
 Facsimile No.: (902) 566-9116628-2045 
 If to Questcor: 

Questcor Pharmaceuticals, Inc. 
 3260 Whipple Road 
 Union City, California 94587 

Attn: Chief Executive Officer 
 Facsimile No. (510) 400 -0799 
 With a copy to: 

Questcor Pharmaceuticals, Inc. 
 3260 Whipple Road 
 Union City, California 94587 

Attn: SVP Pharmaceutical Operations 

Facsimile No. (510) 400 -0799 
  

	 	14.7	Non-Waiver. The failure of either Party to strictly enforce any of the terms or conditions of this Agreement shall not be considered as a waiver of any right hereunder
nor shall it deprive that Party of the right at some other time to insist upon strict adherence to that term or condition or to any other terms or conditions. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 23 of 42	 		 		 	










	 	14.8	Severability. If any section, subsection, sentence or clause of this Agreement shall be adjudged illegal, invalid or unenforceable, such illegality, invalidity or
unenforceability shall not affect the legality, validity or enforceability of this Agreement as a whole or of any section, subsection, sentence or clause hereof not so adjudged, and the remaining terms and provisions of this Agreement shall remain
unimpaired and in full force and effect. 

  

	 	14.9	Paragraph Headings. All paragraph headings in this Agreement are for convenience of reference only and shall not be construed as a limitation of the scope of the
particular sections to which they refer. 

  

	 	14.10	Governing Law and Arbitration. This Agreement will be governed by the laws of the State of California U.S.A., without regard to its, or any other jurisdictions,
conflicts of laws provisions or rulings. Any dispute, claim or controversy that may arise under, out of, in connection with or relating to this Agreement or any breach or default in the performance of the terms and conditions thereof, which cannot
be settled by the Parties, shall be settled by final and binding arbitration in the English language in New York, New York, U.S.A. in accordance with the then-existing Rules of Commercial Arbitration (the “Rules”) promulgated by the
American Arbitration Association (the “AAA”). The arbitrator(s) shall apply the governing law as set forth above in this Section 14.10 and judgment upon the award of the arbitrator(s) may be entered in any court having appropriate
jurisdiction. 

  

	 	14.11	Successors and Assigns. This Agreement shall apply to, inure to the benefit of and be binding upon the Parties hereto and upon their respective successors and permitted
assigns. The Parties agree that this Agreement is not intended by either Party to give any benefits, rights, privileges, actions or remedies to any person, partnership, firm or corporation as a third party beneficiary or otherwise under any theory
of law, except as expressly set forth herein. 

  

	 	14.12	Survival of Obligations. The termination or expiration of this Agreement shall not affect the survival and continuing validity of the Sections entitled
“Representations and Warranties; “Product Recalls”, “Confidentiality”, “Indemnification” and “Limitations on Liability” nor of any other provision that is expressly or by implication intended to continue
in force after such termination or expiration. Termination or expiration of this Agreement shall not relieve either Party from full performance of any obligations incurred prior to the Effective Date of such termination or expiration.


  

	 	14.13	Schedules. All schedules referred to herein form an integral part of this Agreement and are incorporated into this Agreement by such reference.


  

	 	14.14	Review by Legal Counsel. Each of the Parties agrees that it has had the opportunity to review this Agreement with its legal counsel. Accordingly, the rule of
construction that any ambiguity in this Agreement is to be construed against the drafting Party shall not apply. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 24 of 42	 		 		 	









  

	 	14.15	Amendments. No modification, alteration or amendment of this Agreement or any Purchase Order(s) hereunder shall be binding upon the Parties unless contained in a
writing signed and delivered by a duly authorized representative of each respective Party and specifically referring hereto or thereto, as the case may be. 


 

	 	14.16	Counterparts. This Agreement and any amendment or supplement hereto may be executed in any number of counterparts, each of which when executed and delivered shall be
deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument. The execution of this Agreement and any such amendment or supplement by any Party hereto will not become effective until
counterparts hereof have been executed (i.e., signed and delivered) by both Parties hereto. 

  

	 	14.17	Entire Agreement. This Agreement, together with any documents attached hereto, constitutes the entire agreement of the Parties with respect to its subject matter and
merges and supersedes all prior discussions and writings with respect thereto. No modification to this Agreement shall be affected by the acknowledgment or acceptance of any purchase order or shipping instruction forms or similar documents
containing terms or conditions at variance with or in addition to those set forth herein. 

 Notwithstanding the
above, the Mutual Nondisclosure Agreement dated July 12, 2010 (a copy of which is attached hereto as Schedule 7) and the Equipment & Materials Transfer Agreement (a signed copy of which is attached hereto as Schedule 8) shall remain in
full force and effect for the Term, any Extension Period and the period of Confidentiality as set forth in Section 10.1 above, except for the provisions of the Equipment & Materials Transfer Agreement entitled: “Term;
“Termination”, “Development and Supply Agreement” and “Non-Binding Term Sheet”, which shall be superseded hereby. In the event of any direct conflict of the terms and conditions of the Mutual Nondisclosure Agreement and
the Equipment & Materials Transfer Agreement with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall control. The period of confidentiality of the Mutual Nondisclosure Agreement shall be as set
forth in Section 10.1 hereof. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to
be executed by their respective duly authorized representatives to be effective as of the Effective Date set forth above. 
  

									
	QUESTCOR PHARMACEUTICALS, INC.	 		 	BIOVECTRA INC.
					
	Signature:	 	  
	 		 	Signature:	 	  



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 25 of 42	 		 		 	










									
		 	  
	 		 		 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 26 of 42	 		 		 	









  

SCHEDULE 1 
 To the Supply Agreement between Questcor and BioVectra. 
 PRODUCT

 [***] 

  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 27 of 42	 		 		 	









  

SCHEDULE 2 
 To the Supply Agreement between Questcor and BioVectra. 

SPECIFICATIONS 
 [***] 

  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 28 of 42	 		 		 	









  

SCHEDULE 3 
 To the Supply Agreement between Questcor and BioVectra. 
 PRICE 

All prices in USD 
  

					
	 [***]
	  	 [***]
	  	 [***]

			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
		  	[***]	  	


  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 29 of 42	 		 		 	









  

SCHEDULE 4 
 To the April 1 2003 Supply Agreement between Questcor and BioVectra dcl 
  

					
		  	DEVIATION/CHANGE FORM	  	
	CP0006-0	  	BIOVECTRA.	  	

 Standard Operating Procedure for Writing and Managing SOPs 

Attachment 1: Document Creation/Change Control Form. 
  

							
	SOP Title:	 	  
	 		 	


							
				
	SOP Form ID:	 	  
	 	Date:	 	  



 

			
		 	Change Type:
	 ̈	 	Major
	 ̈	 	Minor
		
		 	Check One:
	 ̈	 	Annual Review
	 ̈	 	Revision
	 ̈	 	New issue
	
	Summary of Changes and Justifications
	(Attach additional pages as necessary.)
	  

	  

	  

	  

	  

	  

	  

	
	Comments:	 	  

	  

	  



 

			
	Signature	 	Date
	  
	 	  




  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 30 of 42	 		 		 	









  

	
	 Reviewed by

	 Approved by

	 QA/RA Approval


  

									
	Document Control	  		  		  	
					
	 ̈	  	Revision History Ledger updated	  	  
	  		  	  

		  		  	Signature	  		  	Date
					
	  ̈
	  	Training Requirements Completed	  	  
	  		  	  

		  		  	Signature	  		  	Date
					
	 ̈	  	Read and Understood	  		  		  	
					
	 ̈	  	Additional Training Required (Explain)	  	  
	  		  	
					
		  		  	  
	  		  	

 Attachment 2: Revision History Ledger 

 

									
	 Form ID
	  	 Title
	  	 Revision

#
	  	 Comments
	  	 Performed by

(Initial and Date)

		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 31 of 42	 		 		 	









  

							
	FORM ID	  	            CP0006	  	REVISIONS NO.	  	            Zero (0)
	WRITTEN BY	  	 APPROVED BY


  

					
	QA APPROVAL                EFFECTIVE DATE	 	


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 32 of 42	 		 		 	









  

SCHEDULE 5 
 To the Supply Agreement between Questcor and BioVectra dcl 

QUESTCOR PROVIDED EQUIPMENT AND LOCATION
THEREOF 
 [***] 

  
  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 33 of 42	 		 		 	









  
 Schedule 6 

To the Supply Agreement between Questcor and BioVectra. 

FORMAT OF AN APPROVED CERTIFICATE OF COMPLIANCE 
 To the Supply Agreement between Questcor and BioVectra 
 (as referred to in
Section 9.2.5 of that Agreement) 
 CERTIFICATE OF COMPLIANCE 

[***] 
  

					
	BIOVECTRA INC.	 		 	
			
	 By:
	 		 	  

			
	 Signature
	 		 	
			
	 Date
	 		 	
	
	  

			
	 Print name and title
	 		 	

  

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 34 of 42	 		 		 	









  

SCHEDULE 7 
 To the Supply Agreement between Questcor and BioVectra. 
 MUTUAL
NONDISCLOSURE AGREEMENT (dated July 12, 2010) 
 THIS AGREEMENT is made on July 12, 2010, by and between Questcor Pharmaceuticals,
Inc., a California Corporation located at 3260 Whipple Road, Union City, CA 94587 (“Questcor”) and BioVectra Inc., a corporation organized under the laws of Prince Edward Island and located at (“BioVectra”), 11 Aviation Avenue,
Charlottetown, Prince Edward Island, C1E 0A1 Canada (“BioVectra”). 
 1. Purpose. As part of supply agreement between BioVectra and
Questcor both companies may disclose information it regards as confidential to the other. 
 2. Definition. “Confidential Information”
means any information, technical data, or know-how, including, but not limited to, that which relates to research, development, products, biological materials, chemical compounds, processes, test data, animal studies, clinical trials, markets,
inventions, marketing or finances, which Confidential Information is designated in writing to be confidential or proprietary, or if given orally, is confirmed promptly in writing as having been disclosed as confidential or proprietary. Confidential
Information does not include information, technical data or know-how which (i) is in the possession of the receiving party at the time of disclosure as shown by the receiving party’s files and records immediately prior to the time of
disclosure; or (ii) prior to or after the time of disclosure becomes part of the public knowledge or literature, not as a result of any action or inaction of the receiving party; or (iii) is approved for release by the disclosing party, or
(iv) is at any time disclosed to the receiving party by a third party without, to the knowledge of the receiving party, violation of any obligation of confidentiality. 
 3. Non-Disclosure of Confidential Information. Questcor and BioVectra each agree not to use the Confidential Information disclosed to it by the other party for its own use or for any purpose except as
specified in paragraph 1. Neither will disclose the Confidential Information of the other to third parties or to its own employees and advisors except those employees and advisors who are required to have the information in order to evaluate it.
Each agrees to advise such employees and advisors of the confidential nature of the information they are receiving, and to take all other reasonable steps to protect the secrecy of and avoid disclosure or use of Confidential Information of the other
in order to prevent it from falling into the public domain or the possession of unauthorized persons. Each agrees to notify the other in writing of any misuse or misappropriation of such Confidential Information of the other which may come to its
attention. 
 4. Return of Material. Upon request, any materials or documents which have been furnished by one party to the other will be
returned, accompanied by all copies of such documentation. Except that one copy may be retained for legal archival purposes. 

  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 35 of 42	 		 		 	









  
 5. Patent or Copyright Infringement.
Nothing in this Agreement is intended to grant any rights under any patent or copyright of either party, nor shall this Agreement grant either party any rights in or to the others party’s Confidential Information, except the limited right to
review such Confidential Information solely for the purpose specified in paragraph 1. 
 6. Term. The foregoing commitments in this Agreement
shall terminate on the later of ten (10) years following the date of this Agreement, or ten (10) years following the termination of any business relationship between the parties. 
 7. Miscellaneous. This Agreement shall be binding upon and for the benefit of the undersigned parties, their successors and assigns, provided that Confidential Information may not be assigned without
consent of the disclosing party. Failure to enforce any provision of this Agreement shall not constitute a waiver of any term hereof. 
 8.
Governing Law and Jurisdiction. This Agreement shall be governed by and construed under the laws of the State of California. The federal and state courts within the State of California shall have exclusive jurisdiction to adjudicate any dispute
arising out of this Agreement. 
 9. Remedies. Each party agrees that its obligations hereunder are necessary and reasonable in order to protect
the other party and the other party’s business. Accordingly, each party agrees and acknowledges that any such violation or threatened violation may cause irreparable injury to the other party and that, in addition to any other remedies that may
be available, in law, in equity or otherwise, the other party shall be entitled to obtain injunctive relief against the threatened breach of this Agreement or the continuation of any such breach. 

  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 36 of 42	 		 		 	









  

SCHEDULE 8 
 To the Supply Agreement between Questcor and BioVectra dcl 

EQUIPMENT & MATERIALS TRANSFER AGREEMENT 
  

			
	PARTIES	  	 Questcor Pharmaceuticals, Inc. (“Questcor”)
 Diagnostic Chemicals Limited, doing business as BioVectra (“BIO”)

		
	MATERIAL AND EQUIPMENT TRANSFER	  	Upon reasonable prior notice to RIO, Questcor will cause to be delivered, and BIO will accept for delivery, the Certain manufacturing equipment (the “Equipment”) and the
raw materials (the “Materials”) described and listed on Exhibit A as associated with the commercial production of [***] (the “Concentrate”). Questcor will be responsible for all costs associated with the delivery of the Materials
and Equipment to the Storage Location (defined below), including applicable import/export costs actually and reasonably incurred by BIO. BIO will reasonably assist Questcor to arrange for the delivery and receipt of the Materials and
Equipment.
		
	HANDLING AND STORAGE	  	BIO will (i) handle, store, maintain and deliver the Materials and Equipment in accordance with the terms and conditions of this Term Sheet and applicable laws and regulations and
(ii) take such action as reasonably requested by Questcor in respect of the handling, storage, maintenance or delivery of such Materials and Equipment. BIO will store and maintain the Equipment and the Materials in a secure location within the
premises located at BioVectra DCL, Charlottetown Airport Business Park, 328 Brackley Point Road, Charlottetown, PE C1E, 2E6 (the “Storage Location”) and in a manner that preserves the operation and effectiveness of the Materials and
Equipment, but in no event in a manner less than the specifications described on Exhibit A. Except as directed in writing by Questcor, BIO will not remove the Equipment from its original shipping packaging or otherwise tamper with, remove or
relocate the Equipment or Materials from the Storage Location. BIO will provide Questcor or its designee access to the Equipment and/or Materials in the Storage Location, upon reasonable prior notice. BIO shall immediately notify Questcor at the
address provided below of any breach of this Term Sheet or any theft of and/or damage or unauthorized access to the Equipment and/or Materials.
		
	OWNERSHIP	  	Questcor will retain ownership over all rights in and to the Equipment and Materials delivered to BI0. BIO shall not use, retain for itself or grant to any third party any access or
rights in or to the Materials or Equipment, including, without limitation, the imposition of any levy, lien or encumbrance of any nature whatsoever.
		
	INSURANCE; DAMAGE	  	Questcor will maintain general commercial liability and property insurance covering the Equipment and Materials during the Term in reasonable and customary amounts as it may
determine. BIO will be responsible to Questcor for any loss, damage or destruction of the Equipment and Materials or any claim by any third party with respect to personal injury relating to the Equipment or Materials, in each case to the extent
arising out of BIO’s negligence or willful misconduct.

  

	[***]:	 Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 



  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 37 of 42	 		 		 	










			
	TERM; TERMINATION	  	 This Term Sheet will be in effect from the date last written below until the earlier of (a) the execution by the parries of a definitive
Development and Supply Agreement or (b) June 30, 2003, unless otherwise earlier terminated by either parry in accordance with this Term Sheet or extended in writing by the mutual agreement of the patties (the “Term”).

 
 Either party may terminate this Term Sheet upon [***] prior written notice to the
other for any reason or within [***] upon the uncured material breach by either party; provided however, that Questcor may at any time request the return and delivery of the Materials and/or Equipment to itself or its designee as described
below.

		
	RETURN DELIVERY	  	Promptly upon the request of Questcor (but in no event later than five business days), BIO will prepare the Equipment and Materials for shipment and make them available for transfer
to Questcor or its designee at the Storage Location. Questcor will reimburse BIO with respect to its reasonable and actual costs incurred in connection with the foregoing and will bear the costs of transporting the Equipment and/or Materials from
the Storage Location.
		
	FEES	  	BIO will handle and store the Equipment and Materials in consideration for the negotiation by the parties of a Development and Supply Agreement as described herein and no additional
fees or charges will apply,
		
	QUALITY AUDIT	  	At a time as mutually agreed by the parties, BIO will permit Questcor, at no Cost to Questcor, access to its facilities, records and personnel necessary for Questcor to conduct a
Quality System Audit. Questcor will bear the costs of conducting such audit.
		
	DEVELOPMENT AND SUPPLY AGREEMENT	  	Subject to the successful completion of the Quality Audit described above, the parties will use their good faith, Commercially reasonable efforts to negotiate a definitive
Development and Supply Agreement pursuant to which BIO will provide the Concentrate for Questcor’s commercial requirements.
		
		  	[***]
		
	GOVERNING LAW	  	This Term Sheet and the terms of the definitive agreement will be governed by the laws of the State of California, United States, without regard to its conflicts of
laws.
		
	CONFIDENTIALITY	  	The parties agree that the contents of this Term Sheet and any and all information provided by one party to the other pursuant to this Term Sheet shall be “Confidential
Information” subject to the terms of that certain Mutual Nondisclosure Agreement between Questcor and BIO dated as of August 15, 2002.


 

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 38 of 42	 		 		 	









  

			
	NON-BINDING TERM SHEET	  	The terms provided in the paragraph entitled “Supply Agreement” are for discussion purposes only, and such terms shall not constitute a binding agreement, an offer to
enter into a binding agreement or an amendment to or termination of the certain terms and conditions provided to Questcor by BIO in a letter dated March 18, 2003 (the “Non-Binding Terms”). The Non-Binding Terms and any proposals
contained herein are subject to additional due diligence, the negotiation: of a definitive. agreement, the terms and conditions provided to Questcor by BIO in a letter dated March 18, 2003, and approval by the parties’ respective Board of
Directors.
		
		  	Notwithstanding the foregoing, the parties agree and acknowledge that all provisions other than the Non-Binding Terms will constitute a binding agreement between the parties as of
the date last written below. It is the intention of BIO and Questcor to promptly and in good faith negotiate and finalize a definitive agreement regarding the terms and conditions set forth herein and other usual and customary terms for transactions
of this type. In the event that the parties fail to reach a definitive agreement on or before June 30, 2003 or otherwise extend the term hereof by mutual agreement in writing, this Term Sheet shall terminate as of June 30, 2003 and be of no further
force and effect, except for provisions regarding confidentiality. In such event, BIO shall promptly return the Materials and Equipment to Questcor in accordance with the paragraph entitled “Return & Delivery”


 

									
	QUESTOR PHARMACEUTICALS, INC.	 		 	DIAGNOSTIC CHEMICALS LIMITED
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  



									
					
	Address:	 		 		 	Address:	 	


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 39 of 42	 		 		 	









  
 EXHIBIT A

 Equipment Description and Inventory: 
 (see attached list) 
 [***] 

 

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 40 of 42	 		 		 	









  
 EQUIPMENT FOR HP ACTHAR
GEL 
 TRUCK 1 
 TRUCK I

 [***] 

 

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 41 of 42	 		 		 	









  
 EQUIPMENT FOR HP ACTHAR
GEL 
 TRUCK 2 
 TRUCK 2

 [***] 

 

	[***]:	Certain confidential information contained in this document marked with [***] has been omitted and filed separately with the Securities and Exchange Commission pursuant
to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 


  

									
		  		 		 	  ̈

Questcor
	 	  ̈

BioVectra

	BioVectra	  	Page 42 of 42